Lisinopril Market Report 2025

This Lisinopril market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The lisinopril market size has grown strongly in recent years. It will grow from $1.76 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased accessibility, lifestyle shifts, increased screening programs, increased accessibility of generic lisinopril, and increased patient adherence.

The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising prevalence of hypertension and cardiovascular diseases, generic versions and cost-effectiveness, growing awareness and early diagnosis, growing demand for effective treatments, and aging population. Major trends in the forecast period include innovations in drug delivery, need for enhanced and patient-centric drug delivery approaches, demand for cost-effective solutions, demand for effective treatments for heart failure, and demand for effective treatments for diabetic kidney disease.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the lisinopril market in the future. Cardiovascular diseases (CVDs) refer to a variety of conditions that affect the heart and blood vessels. The rising incidence of these diseases can be attributed to factors such as population growth, aging, risk factors, and the inadequate implementation of effective prevention and treatment strategies. Lisinopril aids in managing cardiovascular diseases primarily by lowering blood pressure and reducing the strain on the heart and kidneys. It works by inhibiting the production of angiotensin II, promoting blood vessel dilation, reducing blood volume, and protecting organs from damage. For example, in May 2024, the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, reported 5,302 deaths from ischemic heart diseases, a slight increase from 5,290 deaths in 2022. Therefore, the growing prevalence of cardiovascular diseases is fueling the growth of the lisinopril market.

The growing prevalence of hypertension is expected to boost the lisinopril market. Hypertension, or high blood pressure, is a condition where the force of blood against artery walls is consistently too high. Factors such as an unhealthy diet, sedentary lifestyle, aging population, and long-term stress contribute to the increasing prevalence of hypertension. Lisinopril effectively manages hypertension by blocking the formation of angiotensin II, leading to blood vessel relaxation, reduced blood volume, and lower blood pressure. For instance, the World Health Organization reported in March 2023 that around 1.28 billion adults aged 30-79 worldwide had hypertension. Therefore, the increasing prevalence of hypertension is driving the lisinopril market.

In January 2024, Sun Pharmaceutical Industries Limited, an Indian pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd for $347.73 million. This acquisition allows Sun Pharma to expand its portfolio by incorporating Taro's expertise in generic and specialty medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Taro Pharmaceutical Industries Ltd, a US-based company, offers lisinopril.

Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca Plc, Vitaris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Hetero Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Metrochem API Private Limited, Calyx Chemicals & Pharmaceuticals Limited, Farmhispania Group, Zydus Cadila Healthcare Ltd., Qingdao Qingmei Biotech Co. Ltd., LGM Pharma LLC, Amara Labs Pvt., Sms Lifesciences.

North America was the largest region in the lisinopril market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lisinopril market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lisinopril is a medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It works by reducing certain chemicals that tighten blood vessels, facilitating smoother blood flow and improving the heart's pumping efficiency. Lisinopril is prescribed for adults to treat congestive heart failure and to increase survival rates after a heart attack.

The main brands of lisinopril include Zestoretic, Prinivil, Zestril, among others. Zestoretic is a combination medication containing lisinopril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is used to treat conditions such as hypertension, heart failure, heart attacks, strokes, diabetic kidney disease, among others. It is available in various forms such as tablets and liquid, and is prescribed to different populations including children and adults. These medications are used by various end-users such as hospitals, specialty clinics, and others.

The lisinopril market research report is one of a series of new reports that provides lisinopril market statistics, including lisinopril industry global market size, regional shares, competitors with a lisinopril market share, detailed lisinopril market segments, market trends, and opportunities, and any further data you may need to thrive in the lisinopril industry. This lisinopril market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.